Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activa...
Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling
About this item
Full title
Author / Creator
Zhang, Xiaoling , Zhang, Yan , Jia, Yanan , Qin, Tingting , Zhang, Cuicui , Li, Yueya , Huang, Chengmou , Liu, Zhujun , Wang, Jing and Li, Kai
Publisher
China: Chinese Anti-Cancer Association (CACA), Cancer Biology & Medicine
Journal title
Language
English
Formats
Publication information
Publisher
China: Chinese Anti-Cancer Association (CACA), Cancer Biology & Medicine
Subjects
More information
Scope and Contents
Contents
Bevacizumab is a recombinant humanized monoclonal antibody that blocks vascular endothelial growth factor (VEGF) with clear clinical benefits. However, overall survival of some cancer types remains low owing to resistance to bevacizumab therapy. While resistance is commonly ascribed to tumor cell invasion induced by hypoxia-inducible factor (HIF),...
Alternative Titles
Full title
Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_fbbad33eb12c4e628ba45271cff2abd9
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fbbad33eb12c4e628ba45271cff2abd9
Other Identifiers
ISSN
2095-3941
DOI
10.20892/j.issn.2095-3941.2019.0215
